Kapoor Rakesh, Das Namrata, Miriyala Raviteja, Sood Ashwani, Oinam Arun, Singh Navneet
Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Phys Imaging Radiat Oncol. 2020 Mar 27;13:50-54. doi: 10.1016/j.phro.2020.03.005. eCollection 2020 Jan.
Radiotherapy treatment planning of radical doses for concurrent chemoradiation in Stage III non-small-cell lung cancer (NSCLC) presents many challenges. This dosimetric study aimed to analyse the impact of spatial location of tumour and nodal burden in limiting the achievement of normal organ constraints and the use of appropriate radiotherapy technique to address it.
Fifteen Stage III NSCLC patients underwent F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) based treatment planning. VMAT (Volumetric Modulated Arc Radiotherapy) plans were made for all patients treated by 3D-CRT (3-Dimensional Conformal Radiotherapy). A binomial logistic regression was performed to ascertain the tumour and nodal characteristics that decreased the likelihood of being planned to 60 Gy.
Inability to achieve normal tissue constraints, particularly spinal cord dose to less than 50 Gy, during initial planning by the assigned treatment technique was the primary dose limiting factor in four patients (p = 0.02). Alternate VMAT plans could achieve the dose constraints where 3D-CRT was unsuccessful in patients with bulky central disease in two patients. This technique fell short when there was gross vertebral body erosion.
For tumours with bulky central disease, VMAT should be preferred. With gross vertebral body erosion, even VMAT falls short if the planning target volume includes the spinal cord. In a subset of Stage III NSCLC upfront chemoradiation to radical doses may not be feasible.
III期非小细胞肺癌(NSCLC)同步放化疗根治性剂量的放射治疗计划面临诸多挑战。本剂量学研究旨在分析肿瘤的空间位置和淋巴结负荷对限制正常器官剂量限制实现的影响,以及采用适当的放射治疗技术来解决这一问题。
15例III期NSCLC患者接受基于氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)/计算机断层扫描(CT)的治疗计划。为所有接受三维适形放疗(3D-CRT)的患者制定容积调强弧形放疗(VMAT)计划。进行二项式逻辑回归分析,以确定降低计划剂量至60 Gy可能性的肿瘤和淋巴结特征。
在最初计划中,采用指定治疗技术无法实现正常组织剂量限制,尤其是脊髓剂量低于50 Gy,这是4例患者的主要剂量限制因素(p = 0.02)。对于两名中央型大肿块疾病患者,当3D-CRT未能成功实现剂量限制时,替代的VMAT计划可以实现剂量限制。当存在椎体明显侵蚀时,该技术效果不佳。
对于中央型大肿块疾病的肿瘤,应首选VMAT。如果计划靶体积包括脊髓,即使是VMAT,在椎体明显侵蚀的情况下也可能无法达到要求。在一部分III期NSCLC患者中, upfront同步放化疗至根治性剂量可能不可行。